Lv2
190 积分 2023-05-16 加入
The emerging field of oncolytic virus-based cancer immunotherapy
2天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
2个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
2个月前
已完结
Diagnostic criteria and evolving molecular characterisation of pulmonary neuroendocrine carcinomas
3个月前
已完结
Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD
4个月前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
4个月前
已完结
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
4个月前
已完结
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine
5个月前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
5个月前
已完结
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
5个月前
已完结
皖公网安备34019202002308
